The effect of herpes zoster vaccines on incident dementia in England: Protocol for an OpenSAFELY regression discontinuity study
Walker, V.; Schaffer, A. L.; Hulme, W. J.; Wood, C.; Tamborska, A.; Walker, A. J.; MacKenna, B.; Goldacre, B.; Sterne, J. A. C.; Geldsetzer, P. A. C.
Show abstract
The English national shingles vaccination programme was officially launched on 1 September 2013 using the live attenuated herpes zoster vaccine Zostavax and updated on 1 September 2023 to replace Zostavax with the two-dose, non-live, recombinant subunit herpes zoster vaccine Shingrix. A study using a regression discontinuity design, conducted following the introduction of the herpes zoster vaccination programme on 1 September 2013 in Wales and using the SAIL databank to analyse Welsh routinely collected data, suggested that Zostavax vaccination reduced the probability of a new dementia diagnosis by approximately 20% over a seven-year follow-up period. The effects of Zostavax and Shingrix on incident dementia in England have not been published to date. This protocol describes a regression discontinuity study to study the effect of herpes zoster vaccines on incident dementia in England using linked electronic health records from OpenSAFELY.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Dementias Platform UK Clinical Studies and Great Minds register: Protocol of a targeted brain health studies re-contact database 94%
- Developing a core outcome set for interventions in people with mild cognitive impairment: study protocol 91%
- Digital game-based interventions for cognitive training in healthy adults and adults with cognitive impairment: Protocol for a two-part systematic review and meta-analysis 90%
Similar papers in this journal
- Hospital-treated infectious diseases and the risk of dementia: multicohort study with replication in the UK Biobank 92%
- Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong 91%
- Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study) 90%
Similar papers in this journal
- Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study 92%
- Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany 91%
- COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021 90%
Similar papers in this journal
- Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY 91%
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021 90%
- Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July – November 2021 90%
Similar papers in this journal
- Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England 93%
- Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY 91%
- Waning effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccines over six months since second dose: a cohort study using linked electronic health records 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.